Amphastar Pharmaceuticals
AMPH
263 hedge funds and large institutions have $1.31B invested in Amphastar Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 84 increasing their positions, 100 reducing their positions, and 50 closing their positions.
220% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $318K
0.39% more ownership
Funds ownership: 72.74% → 73.14% (+0.39%)
6% less funds holding
Funds holding: 279 → 263 (-16)
16% less repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 100
24% less capital invested
Capital invested by funds: $1.72B → $1.31B (-$412M)
28% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 50
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$61.6M |
| 2 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
+$20.1M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$19.5M |
| 4 |
SFM
Systematic Financial Management
Teaneck,
New Jersey
|
+$11.3M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$51.4M |
| 2 |
BCM
Boone Capital Management
Atlanta,
Georgia
|
-$15.4M |
| 3 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$13.5M |
| 4 |
Neuberger Berman Group
New York
|
-$11M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$8.99M |
AMPH Hedge Fund Activity: Q4 2024 in Review
263 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q4 2024, worth a combined $1.31B — down 24% from $1.72B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of AMPH and 36 opened new positions — a net loss of 14 holders — while 100 trimmed existing stakes and 84 added.
The largest buyer was Pacer Advisors, adding an estimated $61.6M. The largest seller was Federated Hermes, cutting an estimated $51.4M.
- 263 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q4 2024, down from 279 in Q3 2024.
- Funds reported $1.31B of Amphastar Pharmaceuticals stock for Q4 2024, down 24% quarter-over-quarter.
- 36 funds opened new Amphastar Pharmaceuticals positions in Q4 2024 and 50 closed out, a net change of -14 holders.
- The largest Amphastar Pharmaceuticals buyer in Q4 2024 was Pacer Advisors, an estimated $61.6M added.
- The largest Amphastar Pharmaceuticals seller in Q4 2024 was Federated Hermes, an estimated $51.4M sold.
Based on aggregated 13F filings for Q4 2024.